Mozelle Thompson, former FTC commissioner, joins CNBC's 'Squawk on the Street' to discuss Perplexity's bid for Google's Chrome.

Cisco Systems Inc. is scheduled to report earnings after Wednesday's close. The stock hit a record high of $82/share in March 2000 and is currently trading near $70/share.

Shares of CAVA Group Inc (NYSE:CAVA) are spiraling this morning, despite beating second-quarter earnings estimates with $0.16 per share.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Enterprise Products Partners remains a top pick in midstream due to strong cash flow, low leverage, and a high, reliable yield. Despite a recent share price dip, fundamentals are robust: rising profits, growing cash flows, and attractive valuation versus peers. Management is driving future growth through $6 billion in capital projects and strategic acquisitions to capture rising U.S. hydrocarbon demand.

EPD's 16% surge in a year is backed by major midstream projects, but rising competition may slow its export gains.

Roblox's soaring growth and viral hits drive record engagement. However, high costs, losses and a rich valuation raise caution.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of LifeMD, Inc. (NASDAQ: LFMD) resulting from allegations that LifeMD may have issued materially misleading business information to the investing public. So What: If you purchased LifeMD securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MarineMax, Inc. (“MarineMax” or the “Company”) (NYSE: HZO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The legal-themed advertisement builds on a Superbowl 2024 campaign, and sees Heidi N Closet and Rife try to defend their clients from overpriced beauty products.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dow Inc. (“Dow” or the “Company”) (NYSE: DOW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Alico, Inc. (NASDAQ:ALCO ) Q3 2025 Earnings Call August 13, 2025 8:30 AM ET Company Participants Bradley Heine - Chief Financial Officer & Accounting Officer John E. Kiernan - President, CEO & Director Conference Call Participants Brandon B.

Toast's 78% surge in a year highlights strong growth and innovation, but lofty valuation and macro headwinds loom large.

BEN hits a 52-week high on strong AUM growth, acquisitions and solid capital returns but rising expenses pose risks ahead.

NBIS posts massive Q2 growth and ups ARR forecast, but faces stiff competition, high spending and scaling risks ahead.

Franco-Nevada Corporation posted record Q2 revenue and earnings, driven by historic gold prices, strong portfolio performance, and industry-leading margins. Valuation remains at a significant premium, reflecting market confidence but leaving limited short-term upside. Diversification across gold, PGM, and energy assets provides resilience against single-commodity volatility.

FSLR's risk-reward profile is a lot more compelling upon the clarity from One Big Beautiful Bill, with the 45x tax credits likely to sustain its rich profit margins. This is on top of the strategic monetization from the tax credit transfers, allowing the management to fund the ongoing capex expansions in the US. Combined with the discounted valuations, healthy balance sheet, & FQ2'25 new bookings, we can understand why the stock has recorded rich recoveries since the April 2025 bottom.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in obesity, cardiovascular, and rare diseases, including promising drugs like oral semaglutide and Mim8. Shareholder returns are supported by strong free cash flow, double-digit profit growth, and disciplined capital expenditures for future expansion.

Amazon has begun adding perishable groceries to its Same-Day Delivery service in the United States.